Geen chemotherapie na operatie voor 70% van vrouwen met vroege borstkanker

Bronnen:

1. Sparano JA, Gray RJ, Wood WC, et al. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. ASCO 2018. J Clin Oncol 36, 2018 (suppl; abstr LBA1).